Assessing the immunogenicity of biopharmaceuticals

Immunogenicity of therapeutic biopharmaceuticals can impact both the efficacy and the safety of the product. Assessment of anti-drug antibodies (ADAs) as well as neutralizing antibodies (NAbs) is a fundamental part of immunogenicity testing. 

By attending this webinar, you will learn:

how the Gyrolab™ platform automates drug-tolerant ADA immunoassays in a time-efficient way using small volumes of patient samples and reagentshow iLite® Assay Ready reporter gene cell lines are designed to overcome limitations of conventional cell-based assays in the assessment of neutralizing antibodies